Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 1999

View Archived Issues

Anti-PECAM-1 antisense compounds for inflammation, cell hyperproliferation designed at Isis

AtheroGenics commences phase II trial for treatment of postangioplasty restenosis

HMR to acquire Ariad's interest in 50/50 genomics joint venture

MediGene in-licenses etomoxir for treatment of CHF

Procept expands human clinical trials of PRO-2000 Gel

Alliance seeks FDA approval for new ultrasound contrast agent

Newly issued U.S. patent covers Axonyx's breakthrough treatment for cognition disorders

SciClone broadens program for cystic fibrosis therapy

Ivax enhances R&D pipeline with purchase of IDR

Six new drug candidates enter the R&D pipeline at Sankyo

Rotamase inhibitors with neurotrophic properties described by Pfizer

Novel caspase-1 inhibitors designed at Vertex

Novo Nordisk presents new compounds particularly useful in the treatment of NIDDM

Bracco and Dibra team up on the development of new MRI agents

Inhibitors of tumor cell proliferation patented by Roche

Cochleates show promise as oral delivery vehicle for amphotericin B

International team develops new anti-HIV agents active against resistant viruses

TAP aims for 1999 FDA submission for cefditoren; encouraging data reported at ICAAC

Treatment of complex bronchopulmonary disorders in pediatric patients with polyoxidonium

Study in patients with severe pulmonary hypertension indicates efficacy of prostacyclin derivative

FDA accepts DigiTAb filing for review

Ciclosporin derivative SDZ-SCP-764: pharmacokinetics and distribution following inhaled dosing

Clinical trials of lodenosine suspended pending review of safety data

Anti-IgE MAb improves quality of life in allergy sufferers

Anti-Infective Drugs Advisory Committee to review two quinolones next week

The Liposome Company to resubmit its NDA for Evacet

Patent application filed covering new use of CBP-1011 for IBD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...